Editas Medicine Quarterly Income Statements Chart
Quarterly
|
Annual
Editas Medicine Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-09-03 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-09-03 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-03 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| collaboration and other research and development revenues | 3,578,000 | 4,658,000 | 30,604,000 | 61,000 | 513,000 | 1,135,000 | 60,049,000 | 5,336,000 | 2,887,000 | 9,851,000 | 6,536,000 | 42,000 | 6,362,000 | 6,771,000 | 12,469,000 | 6,197,000 | 379,000 | 6,499,000 | 11,419,000 | 62,841,000 | 10,749,000 | 5,723,000 | 12,284,000 | 3,848,000 | 2,330,000 | 2,069,000 | 6,119,000 | 14,519,000 | 7,372,000 | 3,927,000 | 2,515,250 | 6,282,000 | 3,097,000 | 682,000 | 1,288,750 | 962,000 | 3,388,000 | |||||
| operating expenses: | ||||||||||||||||||||||||||||||||||||||||||
| research and development | 16,181,000 | 26,593,000 | 48,611,000 | 47,639,000 | 54,210,000 | 48,787,000 | 69,556,000 | 40,512,000 | 29,779,000 | 37,804,000 | 51,998,000 | 41,326,000 | 43,659,000 | 37,976,000 | 37,553,000 | 29,265,000 | 33,753,000 | 41,937,000 | 61,504,000 | 33,916,000 | 28,007,000 | 34,570,000 | 34,789,000 | 22,702,000 | 23,565,000 | 15,842,000 | 19,194,000 | 17,443,000 | 32,718,000 | 21,300,000 | -56,205,000 | 20,396,000 | 17,318,000 | 19,021,000 | -29,614,000 | 10,832,000 | 10,430,000 | 8,882,000 | ||||
| general and administrative | 12,859,000 | 13,375,000 | 16,354,000 | 18,088,000 | 18,206,000 | 19,339,000 | 14,455,000 | 14,987,000 | 17,202,000 | 23,008,000 | 17,984,000 | 16,236,000 | 16,937,000 | 19,545,000 | 16,526,000 | 16,185,000 | 22,027,000 | 21,445,000 | 15,787,000 | 19,936,000 | 14,081,000 | 17,769,000 | 16,917,000 | 15,734,000 | 14,414,000 | 17,489,000 | 13,178,000 | 13,334,000 | 14,311,000 | 14,186,000 | -35,607,000 | 12,635,000 | 11,894,000 | 12,288,000 | -32,005,000 | 11,295,000 | 12,158,000 | 9,762,000 | ||||
| restructuring and impairment charges | 26,082,000 | 40,853,000 | ||||||||||||||||||||||||||||||||||||||||
| total operating expenses | 55,122,000 | 80,821,000 | 77,197,000 | 65,727,000 | 72,416,000 | 68,126,000 | 84,011,000 | 55,499,000 | 46,981,000 | 60,812,000 | 69,982,000 | 57,562,000 | 60,596,000 | 57,521,000 | 54,079,000 | 45,450,000 | 55,780,000 | 63,382,000 | 77,291,000 | 53,852,000 | 42,088,000 | 52,339,000 | 51,706,000 | 38,436,000 | 37,979,000 | 33,331,000 | 32,372,000 | 30,777,000 | 47,029,000 | 35,486,000 | -91,812,000 | 33,031,000 | 29,212,000 | 31,309,000 | -61,619,000 | 22,127,000 | 22,588,000 | 18,644,000 | ||||
| operating income | -51,544,000 | -76,163,000 | -46,593,000 | -65,666,000 | -71,903,000 | -66,991,000 | -23,962,000 | -50,163,000 | -44,094,000 | -50,961,000 | -63,446,000 | -57,520,000 | -54,234,000 | -50,750,000 | -41,610,000 | -39,253,000 | -55,401,000 | -56,883,000 | -65,872,000 | 8,989,000 | -31,339,000 | -46,616,000 | -39,422,000 | -34,588,000 | -35,649,000 | -31,262,000 | -26,253,000 | -16,258,000 | -39,657,000 | -31,559,000 | 81,751,000 | -26,749,000 | -26,115,000 | -30,627,000 | 56,464,000 | -21,165,000 | -19,200,000 | -17,839,000 | ||||
| yoy | -28.31% | 13.69% | 94.45% | 30.91% | 63.07% | 31.46% | -62.23% | -12.79% | -18.70% | 0.42% | 52.48% | 46.54% | -2.11% | -10.78% | -36.83% | -536.68% | 76.78% | 22.02% | 67.09% | -125.99% | -12.09% | 49.11% | 50.16% | 112.74% | -10.11% | -0.94% | -132.11% | -39.22% | 20.85% | -366.92% | -147.37% | 59.52% | -416.52% | |||||||||
| qoq | -32.32% | 63.46% | -29.05% | -8.67% | 7.33% | 179.57% | -52.23% | 13.76% | -13.48% | -19.68% | 10.30% | 6.06% | 6.87% | 21.97% | 6.00% | -29.15% | -2.61% | -13.65% | -832.81% | -128.68% | -32.77% | 18.25% | 13.98% | -2.98% | 14.03% | 19.08% | 61.48% | -59.00% | 25.66% | -138.60% | -405.62% | -14.73% | -154.24% | -366.78% | 7.63% | |||||||
| operating margin % | ||||||||||||||||||||||||||||||||||||||||||
| other income, net: | ||||||||||||||||||||||||||||||||||||||||||
| other income | -1,758,000 | -425,000 | -5,000 | -1,000 | 6,000 | -14,000 | -7,000 | -1,584,000 | 1,289,000 | 1,000 | 235,000 | -234,000 | -1,736,000 | 19,000 | -1,000 | 21,000 | 3,145,000 | -1,396,000 | 7,175,000 | 7,333,000 | 7,000 | -33,000 | -68,000 | -44,000 | -4,000 | 154,000 | 182,000 | -476,000 | 196,000 | 122,000 | 140,000 | 4,000 | 3,000 | 5,000 | -30,000 | |||||||
| interest related to sale of future revenues | -2,020,000 | -2,216,000 | ||||||||||||||||||||||||||||||||||||||||
| interest income | 2,087,000 | 2,716,000 | 1,201,000 | 3,530,000 | 4,297,000 | 5,035,000 | 5,102,000 | 5,144,000 | 3,811,000 | 3,509,000 | 1,419,000 | 1,793,000 | 546,000 | 469,000 | 1,910,000 | 152,000 | 146,000 | 134,000 | 228,000 | 226,000 | 592,000 | 1,559,000 | 1,645,000 | 1,680,000 | 1,931,000 | 2,057,000 | 1,202,000 | 1,024,000 | 780,000 | 438,000 | -275,500 | -46,000 | -446,000 | -610,000 | 104,750 | 142,000 | 153,000 | 124,000 | ||||
| total other income | -1,691,000 | 75,000 | 1,198,000 | 3,525,000 | 4,296,000 | 5,041,000 | 5,088,000 | 5,144,000 | 3,804,000 | 1,925,000 | 2,708,000 | 1,794,000 | 781,000 | 235,000 | 174,000 | 171,000 | 145,000 | 155,000 | 3,373,000 | -1,170,000 | 7,767,000 | 8,892,000 | 1,652,000 | 1,647,000 | 1,863,000 | 2,013,000 | 1,198,000 | 1,020,000 | 934,000 | 620,000 | 626,000 | 150,000 | -324,000 | -470,000 | -415,000 | 145,000 | 158,000 | 94,000 | ||||
| net income | -53,235,000 | -76,088,000 | -45,395,000 | -62,141,000 | -67,607,000 | -61,950,000 | -18,874,000 | -45,019,000 | -40,290,000 | -49,036,000 | -60,738,000 | -55,726,000 | -53,453,000 | -50,515,000 | -41,436,000 | -39,082,000 | -55,256,000 | -56,728,000 | -62,499,000 | 7,819,000 | -23,572,000 | -37,724,000 | -37,770,000 | -32,941,000 | -33,786,000 | -29,249,000 | -25,055,000 | -15,238,000 | -38,723,000 | -30,939,000 | 82,377,000 | -26,599,000 | -26,439,000 | -31,097,000 | 56,049,000 | -21,020,000 | -19,042,000 | -17,745,000 | ||||
| yoy | -21.26% | 22.82% | 140.52% | 38.03% | 67.80% | 26.34% | -68.93% | -19.21% | -24.63% | -2.93% | 46.58% | 42.59% | -3.26% | -10.95% | -33.70% | -599.83% | 134.41% | 50.38% | 65.47% | -123.74% | -30.23% | 28.98% | 50.75% | 116.18% | -12.75% | -5.46% | -130.42% | -42.71% | 17.02% | -364.90% | -147.46% | 63.31% | -415.86% | |||||||||
| qoq | -30.03% | 67.61% | -26.95% | -8.08% | 9.13% | 228.23% | -58.08% | 11.74% | -17.84% | -19.27% | 8.99% | 4.25% | 5.82% | 21.91% | 6.02% | -29.27% | -2.59% | -9.23% | -899.32% | -133.17% | -37.51% | -0.12% | 14.66% | -2.50% | 15.51% | 16.74% | 64.42% | -60.65% | 25.16% | -137.56% | -409.70% | -14.98% | -155.48% | -366.65% | 7.31% | |||||||
| net income margin % | ||||||||||||||||||||||||||||||||||||||||||
| net income per share | -0.63 | -0.92 | -0.55 | -0.75 | -0.82 | -0.76 | -0.21 | -0.55 | -0.56 | -0.71 | -0.88 | -0.81 | -0.78 | -0.74 | -0.61 | -0.57 | -0.81 | -0.86 | -1.05 | 0.13 | -0.43 | -0.69 | -0.73 | -0.66 | -0.69 | -0.6 | -0.52 | -0.32 | -0.82 | -0.67 | -3.8 | -0.64 | -0.65 | -0.85 | -4.07 | -0.59 | -0.54 | -0.8 | ||||
| weighted-average common shares outstanding, basic and diluted | 84,412,200 | 83,055,066 | 82,338,220 | 82,485,199 | 82,310,368 | 81,938,839 | 75,965,633 | 81,648,250 | 71,376,678 | 68,924,180 | 68,664,822 | 68,736,125 | 68,640,858 | 68,484,978 | 67,619,388 | 67,877,126 | 65,992,395 | 58,609,389 | 55,346,052 | 54,590,194 | 49,983,329 | 49,820,455 | 49,070,574 | 48,838,229 | 47,097,735 | 47,414,271 | 46,952,059 | 45,992,008 | 300,480 | 41,307,092 | 300,480 | 40,830,161 | 36,485,421 | 300,480 | 35,505,429 | 300,480 | 35,286,719 | 22,280,797 | ||||
| weighted-average common shares outstanding, basic | 68,219,742 | 62,144,118 | ||||||||||||||||||||||||||||||||||||||||
| weighted-average common shares outstanding, diluted | 68,219,742 | 62,697,173 | ||||||||||||||||||||||||||||||||||||||||
| reconciliation of net income to net income attributable to common stockholders: | ||||||||||||||||||||||||||||||||||||||||||
| accretion of redeemable convertible preferred stock to redemption value | 22,000 | -47,000 | ||||||||||||||||||||||||||||||||||||||||
| net income attributable to common stockholders | 82,352,000 | -26,599,000 | -26,439,000 | -31,097,000 | 56,071,000 | -21,020,000 | -19,042,000 | -17,792,000 | ||||||||||||||||||||||||||||||||||
| net income and comprehensive loss | -31,097,000 | 56,049,000 | -21,020,000 | -19,042,000 | -17,745,000 | |||||||||||||||||||||||||||||||||||||
| collaboration revenue | 805,000 |
We provide you with 20 years income statements for Editas Medicine stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Editas Medicine stock. Explore the full financial landscape of Editas Medicine stock with our expertly curated income statements.
The information provided in this report about Editas Medicine stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.